Once again, AstraZeneca had a healthy quarter, continuing its strong performance in oncology and in China. Although, operating margins came under pressure. While the company has many high-potential drugs in the pipeline, especially in oncology, we maintain a somewhat cautious stance as competition is intensifying and the group’s pipeline execution has historically had a mixed track record.
25 Oct 2019
The 3 Cs – Cancer, China, and Caution
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The 3 Cs – Cancer, China, and Caution
AstraZeneca PLC (AZN:LON) | 12,047 83365.2 6.1% | Mkt Cap: 186,756m
- Published:
25 Oct 2019 -
Author:
Surbhit Gupta -
Pages:
4
Once again, AstraZeneca had a healthy quarter, continuing its strong performance in oncology and in China. Although, operating margins came under pressure. While the company has many high-potential drugs in the pipeline, especially in oncology, we maintain a somewhat cautious stance as competition is intensifying and the group’s pipeline execution has historically had a mixed track record.